These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36036376)

  • 1. Antibacterial and antibiofilm activities of fosfomycin combined with rifampin against carbapenem-resistant Pseudomonas aeruginosa.
    Liu Y; Ma W; Li M; Wu J; Sun L; Zhao W; Sun S
    Lett Appl Microbiol; 2022 Dec; 75(6):1559-1568. PubMed ID: 36036376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa.
    Di X; Wang R; Liu B; Zhang X; Ni W; Wang J; Liang B; Cai Y; Liu Y
    J Antibiot (Tokyo); 2015 Sep; 68(9):551-5. PubMed ID: 25805069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
    Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
    Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic resistance, biofilm production ability and genetic diversity of carbapenem-resistant Pseudomonas aeruginosa strains isolated from nosocomial infections in southwestern Iran.
    Heidari R; Farajzadeh Sheikh A; Hashemzadeh M; Farshadzadeh Z; Salmanzadeh S; Saki M
    Mol Biol Rep; 2022 May; 49(5):3811-3822. PubMed ID: 35169997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amikacin and cefoperazone/sulbactam alone or in combination against carbapenem-resistant Pseudomonas aeruginosa.
    Cai Y; Yang D; Wang J; Wang R
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):186-190. PubMed ID: 29486972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk factors for healthcare-associated infection caused by carbapenem-resistant Pseudomonas aeruginosa.
    Tsao LH; Hsin CY; Liu HY; Chuang HC; Chen LY; Lee YJ
    J Microbiol Immunol Infect; 2018 Jun; 51(3):359-366. PubMed ID: 28988663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, Risk Factors, and Molecular Epidemiology of Intestinal Carbapenem-Resistant Pseudomonas aeruginosa.
    Hu Y; Qing Y; Chen J; Liu C; Lu J; Wang Q; Zhen S; Zhou H; Huang L; Zhang R
    Microbiol Spectr; 2021 Dec; 9(3):e0134421. PubMed ID: 34817230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.
    Kunakonvichaya B; Thirapanmethee K; Khuntayaporn P; Montakantikul P; Chomnawang MT
    Int J Antimicrob Agents; 2015 May; 45(5):556-7. PubMed ID: 25724628
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa.
    Ma W; Li J; Wang D; Yu C; Sun S
    Lett Appl Microbiol; 2019 Sep; 69(3):198-203. PubMed ID: 31236975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for carbapenem-resistant Pseudomonas aeruginosa infection or colonization in a Chinese teaching hospital.
    Zhang D; Cui K; Wang T; Shan Y; Dong H; Feng W; Ma C; Dong Y
    J Infect Dev Ctries; 2018 Aug; 12(8):642-648. PubMed ID: 31958327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic
    Loose M; Link I; Naber KG; Wagenlehner FME
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
    Avery LM; Sutherland CA; Nicolau DP
    J Med Microbiol; 2019 Jun; 68(6):893-897. PubMed ID: 31050629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome.
    Jeong SJ; Yoon SS; Bae IK; Jeong SH; Kim JM; Lee K
    Diagn Microbiol Infect Dis; 2014 Oct; 80(2):130-5. PubMed ID: 25112900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
    Wi YM; Greenwood-Quaintance KE; Schuetz AN; Ko KS; Peck KR; Song JH; Patel R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections.
    Lin KY; Lauderdale TL; Wang JT; Chang SC
    J Microbiol Immunol Infect; 2016 Feb; 49(1):52-9. PubMed ID: 24662016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of extensively drug-resistant Pseudomonas aeruginosa co-harboring metallo-β-lactamase enzymes with oprD gene downregulation.
    El-Sherbiny GM; Basha AM; Mabrouk MI
    Indian J Med Microbiol; 2022; 40(1):51-56. PubMed ID: 34802794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotics associated with acquisition of carbapenem-resistant Pseudomonas aeruginosa in ICUs: a multicentre nested case-case-control study.
    Coppry M; Jeanne-Leroyer C; Noize P; Dumartin C; Boyer A; Bertrand X; Dubois V; Rogues AM
    J Antimicrob Chemother; 2019 Feb; 74(2):503-510. PubMed ID: 30376042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenem-resistant
    Huang W; Wei X; Xu G; Zhang X; Wang X
    Front Public Health; 2023; 11():1088262. PubMed ID: 36844819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of daptomycin combined with fosfomycin or rifampin on planktonic and adherent linezolid-resistant isolates of Enterococcus faecalis.
    Zheng JX; Sun X; Lin ZW; Qi GB; Tu HP; Wu Y; Jiang SB; Chen Z; Deng QW; Qu D; Yu ZJ
    J Med Microbiol; 2019 Mar; 68(3):493-502. PubMed ID: 30882300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.